The FDA announced it will be reducing, refining and potentially replacing the animal testing requirement for the approval of ...

The FDA previously granted breakthrough therapy designation to ziftomenib for relapsed/refractory NPM1-mutant AML.

On Friday, U.S. Sen. Rand Paul, R-Bowling Green, was joined by three colleagues in reintroducing bipartisan legislation to ...

The FDA granted a positive review for an acute myeloid leukemia drug trial, with initial dosing expected in 2025.

In Actavis Labs. FL, Inc. v. U.S.  (“Actavis”), a recent precedential decision, the Federal Circuit answered an important ...

In this review, we have summarized the recent application of drugs used ... identify potential target pathways and new therapeutic drugs. Although the clinical use of some MS treatment drugs can ...

The recent uptick and rise in popularity of GLP-1 drugs for addressing weight loss and obesity has led to an increase in U.S. litigation ...

SAN FRANCISCO : Artificial intelligence group MLCommons unveiled two new benchmarks that it said can help determine how quickly top-of-the-line hardware and software can run AI applications.

There is some good news on the horizon for millions of people worldwide battling severe back pain as a new drug on the anvil can be a real ‘gamechanger’ for them. The drug promising immense relief ...

(RTTNews) - Milestone Pharmaceuticals (MIST) announced the FDA issued a Complete Response Letter regarding its New Drug Application for CARDAMYST nasal spray, a prescription medication in ...

However, nearly all peptide drugs must be injected as they are rapidly digested in the gut. We have now developed a way of making peptides gut-stable so they can be given orally. This is a new and ...

has accepted its New Drug Application (NDA) resubmission for YUTREPIA™ (treprostinil) inhalation powder to treat pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with ...